...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Stem Cells >Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose‐Derived Stromal/Stem Cell Therapies
【24h】

Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose‐Derived Stromal/Stem Cell Therapies

机译：简明审查：使用脂肪对抗疾病：对非胚芽脂肪衍生的基质/干细胞疗法进行系统审查

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract The objective of this Review is to describe the safety and efficacy of adipose stem/stromal cells (ASC) and stromal vascular fraction (SVF) in treating common diseases and the next steps in research that must occur prior to clinical use. Pubmed, Ovid Medline, Embase, Web of Science, and the Cochrane Library were searched for articles about use of SVF or ASC for disease therapy published between 2012 and 2017. One meta‐analysis, 2 randomized controlled trials, and 16 case series were included, representing 844 human patients. Sixty‐nine studies were performed in preclinical models of disease. ASCs improved symptoms, fistula healing, remission, and recurrence rates in severe cases of inflammatory bowel disease. In osteoarthritis, ASC and SVF improved symptom‐related, functional, radiographic, and histological scores. ASC and SVF were also shown to improve clinical outcomes in ischemic stroke, multiple sclerosis, myocardial ischemia, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, chronic liver failure, glioblastoma, acute kidney injury, and chronic skin wounds. These effects were primarily paracrine in nature and mediated through reduction of inflammation and promotion of tissue repair. In the majority of human studies, autologous ASC and SVF from liposuction procedures were used, minimizing the risk to recipients. Very few serious, treatment‐related adverse events were reported. The main adverse event was postprocedural pain. SVF and ASC are promising therapies for a variety of human diseases, particularly for patients with severe cases refractory to current medical treatments. Further randomized controlled trials must be performed to elaborate potential safety and efficacy prior to clinical use. S tem C ells 2018;36:1311–1328
机译：摘要本综述的目的是描述脂肪茎/基质细胞（ASC）和基质血管分数（SVF）治疗常见疾病以及在临床使用前必须发生的研究中的下一步骤的安全性和有效性。搜索了PubMed，Ovid Medline，Embase，Sembase，Cochrane图书馆，用于2012年和2017年间发布的SVF或ASC用于疾病治疗的文章。一个META分析，2个随机对照试验和16个案例系列被包括在内，代表844名人类患者。在临床前疾病模型中进行六十九项研究。在炎症性肠病严重案例中，ASCS改善症状，瘘管愈合，缓解和复发率。在骨关节炎，ASC和SVF改善症状相关，功能，射线照相和组织学分数。还显示ASC和SVF在缺血性卒中，多发性硬化，心肌缺血，慢性阻塞性肺病，特发性肺纤维化，慢性肝功能衰竭，胶质母细胞瘤，急性肾损伤和慢性皮肤伤口中的临床结果。这些效果主要是旁静脉本质上，通过减少炎症和促进组织修复而介导。在大多数人类研究中，使用来自吸脂程序的自体ASC和SVF，从而最大限度地减少对受体的风险。据报道，很少有严重，治疗相关的不良事件。主要不良事件是后期疼痛。 SVF和ASC是有关各种人类疾病的疗法，特别是对于对目前的医疗治疗难以难以理解的患者。必须进行进一步的随机对照试验，以在临床使用前阐述潜在的安全性和疗效。 STEM C ells 2018; 36：1311-1328

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号